Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 235.07
ZLAB's Cash-to-Debt is ranked higher than
61% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ZLAB: 235.07 )
Ranked among companies with meaningful Cash-to-Debt only.
ZLAB' s Cash-to-Debt Range Over the Past 10 Years
Min: 235.07  Med: No Debt Max: No Debt
Current: 235.07
235.07
No Debt
Debt-to-EBITDA -0.01
ZLAB's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. ZLAB: -0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ZLAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.01  Med: 0 Max: 0
Current: -0.01
-0.01
0
Interest Coverage No Debt
ZLAB's Interest Coverage is ranked higher than
52% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ZLAB: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ZLAB' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 33.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -55.76
ZLAB's ROE % is ranked lower than
82% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ZLAB: -55.76 )
Ranked among companies with meaningful ROE % only.
ZLAB' s ROE % Range Over the Past 10 Years
Min: -55.76  Med: -54.88 Max: -54.88
Current: -55.76
-55.76
-54.88
ROA % -35.86
ZLAB's ROA % is ranked higher than
50% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ZLAB: -35.86 )
Ranked among companies with meaningful ROA % only.
ZLAB' s ROA % Range Over the Past 10 Years
Min: -129.28  Med: -72.95 Max: -29.77
Current: -35.86
-129.28
-29.77
ROC (Joel Greenblatt) % -527.62
ZLAB's ROC (Joel Greenblatt) % is ranked lower than
55% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ZLAB: -527.62 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ZLAB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3943.6  Med: -2309.18 Max: -527.62
Current: -527.62
-3943.6
-527.62
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ZLAB's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ZLAB Guru Trades in Q3 2017

Steven Cohen 5,000 sh (New)
» More
Q4 2017

ZLAB Guru Trades in Q4 2017

Steven Cohen Sold Out
» More
Q1 2018

ZLAB Guru Trades in Q1 2018

Ron Baron 68,000 sh (New)
» More
Q2 2018

ZLAB Guru Trades in Q2 2018

Ron Baron 92,441 sh (+35.94%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ZLAB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-06-30 Add 35.94%$18 - $25.01 $ 16.43-24%92,441
Ron Baron 2018-03-31 New Buy0.01%$20.05 - $26.96 $ 16.43-28%68,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Zai Lab Ltd does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ROCO:4174, XMCE:ROVI, NAS:MGNX, OCSE:BAVA, SHSE:603566, SZSE:002022, XKRX:078160, NAS:NTLA, SHSE:603718, XKRX:003000, SZSE:002872, NAS:BOLD, NAS:ACOR, NAS:ADAP, NAS:RVNC, SZSE:300149, SAU:2070, SHSE:600200, OSTO:HMED, TSXV:CRON » details
Traded in other countries:1ZL.Germany,
Headquarter Location:China
Zai Lab Ltd is a biopharmaceutical company. The company is engaged in discovering or licensing, developing and commercializing proprietary therapeutics in the fields of oncology, autoimmune and infectious diseases.

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. The company operates through the single segment being Developing and commercializing proprietary therapeutics.

Top Ranked Articles about Zai Lab Ltd

Zai Lab Announces Approval of ZEJULA® (Niraparib) for Patients with Relapsed Ovarian Cancer in Hong Kong
Zai Lab Appoints Industry Leader Tao Fu as President & Chief Operating Officer, Expands US Presence
Zai Lab Presents Interim Results of its ongoing Phase 2 study of ZL-2301 (brivanib) in Chinese Patients with Advanced Hepatocellular Carcinoma (HCC) at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Zai Lab Presents Results of its Pharmacokinetics (PK) Study for ZL-2306 (niraparib) in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
Zai Lab to Participate in the Leerink Rare Disease & Immuno-Oncology Roundtable
Zai Lab to Host Conference Call to Discuss its License and Collaboration Agreement with Novocure for Tumor Treating Fields in Greater China
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Announces Proposed Public Offering of American Depositary Shares
Zai Lab Announces Proposed Public Offering of American Depositary Shares

Ratios

vs
industry
vs
history
PB Ratio 4.17
ZLAB's PB Ratio is ranked lower than
54% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ZLAB: 4.17 )
Ranked among companies with meaningful PB Ratio only.
ZLAB' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.72
Current: 4.17
0
5.72
EV-to-EBIT -12.31
ZLAB's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ZLAB: -12.31 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLAB' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.13  Med: 0 Max: 0
Current: -12.31
-26.13
0
EV-to-EBITDA -12.44
ZLAB's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ZLAB: -12.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZLAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.41  Med: 0 Max: 0
Current: -12.44
-26.41
0
Current Ratio 17.78
ZLAB's Current Ratio is ranked higher than
90% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ZLAB: 17.78 )
Ranked among companies with meaningful Current Ratio only.
ZLAB' s Current Ratio Range Over the Past 10 Years
Min: 3.36  Med: 16.26 Max: 19.11
Current: 17.78
3.36
19.11
Quick Ratio 17.78
ZLAB's Quick Ratio is ranked higher than
91% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ZLAB: 17.78 )
Ranked among companies with meaningful Quick Ratio only.
ZLAB' s Quick Ratio Range Over the Past 10 Years
Min: 3.36  Med: 16.26 Max: 19.11
Current: 17.78
3.36
19.11

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.01
ZLAB's Price-to-Net-Cash is ranked higher than
63% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ZLAB: 5.01 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ZLAB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.93  Med: 6.01 Max: 7.09
Current: 5.01
4.93
7.09
Price-to-Net-Current-Asset-Value 4.88
ZLAB's Price-to-Net-Current-Asset-Value is ranked higher than
61% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ZLAB: 4.88 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ZLAB' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.82  Med: 5.9 Max: 6.9
Current: 4.88
4.82
6.9
Price-to-Tangible-Book 4.18
ZLAB's Price-to-Tangible-Book is ranked higher than
54% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ZLAB: 4.18 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ZLAB' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.13  Med: 5.21 Max: 5.91
Current: 4.18
4.13
5.91
Earnings Yield (Greenblatt) % -8.12
ZLAB's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ZLAB: -8.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ZLAB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -9.54  Med: 0 Max: 0
Current: -8.12
-9.54
0

More Statistics

EPS (TTM) $ -1.35
Volatility51.60%
52-Week Range $14.29 - 30.16
Shares Outstanding (Mil)50.61

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}